Abbonarsi

Finding CYP2D6 activity biomarkers by correlating MDMA pharmacokinetic parameters to untargeted metabolomics data - 15/08/22

Doi : 10.1016/j.toxac.2022.06.047 
Yannick Wartmann 1, , Yasmin Schmid 2, Matthas E. Liechti 2, Thomas Kraemer 1, Andrea Steuer 1
1 Department of forensic pharmacology and toxicology, Zurich institute of forensic medicine, Zurich, Switzerland 
2 Department of biomedicine and department of clinical research, University hospital Basel, Basel, Switzerland 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Aim

Cytochrome P450 (CYP) enzymes play a major role in drug metabolism. Many of these enzymes exhibit a huge inter-individual variation in activity, not only attributable to the individual's genotype. Such environmental influences are hardly measurable, let alone their outcome predictable. The actual phenotype is usually determined through administration of well-studied CYP probe substrates – an approach that is obviously unsuitable for forensic investigations, particularly postmortem. Therefore, we aimed at finding alternative biomarkers of the CYP phenotype. Application of metabolomics techniques in theory should reveal endogenous metabolites processed by CYP isoenzymes, which in turn could be indicative for a person's phenotype for particular CYP isoenzymes (e.g. 2D6). In a standard metabolomics approach, features (unidentified metabolites) could be compared between different known CYP genotype/phenotypes. While this approach is most promising, a controlled study needs to be conducted including genotyping and probe-substrate phenotyping. Instead of a new phenotyping study, we aimed to explore the intended approach with a previous crossover study with a typical CYP2D6 substrate (MDMA) and a known inhibitor of CYP2D6 (bupropion) for the general suitability to find endogenous correlates of CYP2D6 activity.

Method

Plasma samples of a controlled MDMA/bupropion crossover study with four experimental test sessions (pretreatment – study day as follows: placebo-placebo, bupropion – placebo, placebo-MDMA, and bupropion-MDMA, n=16 each), initially intended to study pharmacological questions, were reused. Plasma from timepoint 9 from the placebo-placebo and bupropion-placebo session were worked-up by simple protein precipitation and measured with a previously published untargeted metabolomics method (Boxler. Drug Test Anal 2019;11(5):678–696). Briefly, LC-qTOF-MS (Sciex 6600) with reversed-phase (RP) and HILIC chromatography was used in both positive and negative ESI mode. Untargeted data was analysed using msDial 4.8 and a pre-release version of SIRIUS (5.4.1) for structure elucidation and comparison to common databases. Feature peak areas were correlated (spearman) with the ratio of the area under the curve (AUC) of MDMA metabolites/AUC MDMA as determined as the best CYP2D6 correlate in a former targeted analysis (Steuer. Plos One 2016;11:e0150955). Further filter criteria were: fold change between groups of>2 or<0.5 and mean S/N>150.

Results

Out of 24858 features found in RP positive mode, by correlation analysis, 27 features with a spearman correlation greater than 0.55 and with assigned MS/MS and 109 features without MS/MS information were found, respectively. As expected, 3 of the features could be unambiguously identified to be bupropion and its known metabolites. Further 10 features indicated a chlorine cluster, not expected endogenously, which pointed to further fragments/metabolites or artifacts of bupropion. The remaining 14 features could be considered as promising biomarker candidates not related to bupropion and as such as tentative indicators of the respective CYP2D6 phenotype.

Conclusion

Using the pharmacokinetic parameters of MDMA, acting as a CYP2D6 substrate, with and without CYP2D6 inhibition by bupropion and corresponding metabolomics data, we could show, that the metabolome approach is able to find potential biomarkers for actual CYP2D6 status. As unfortunately typical for untargeted metabolomics, final identification of features still remains the bottleneck and requires further investigation. In addition, the applicability of the found biomarkers of course needs to be tested in a larger independent cohort. Ideally, a ratio of features that are substrate and product of the enzyme could be formed to increase the predictive power of this approach.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 34 - N° 3S

P. S44 - Settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • An illicit drug early warning system in Victoria, Australia: The role of forensic toxicology in clinical casework
  • Jennifer Schumann, Syrjanen Syrjanen, John Fitzgerald, Dimitri Gerostamoulos, Shaun Greene
| Articolo seguente Articolo seguente
  • Fate of fentanyl after formalin-fixed tissues: About an authentic case and a stability study
  • Alice Ameline, Adeline Blanchot, Laurie Gheddar, Nadia Arbouche, Emilie Feisthauer, Jean-Sébastien Raul, Anne-Laure Pelissier, Pascal Kintz

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.